It is my view that B-cell therapy will likely become an important part of the treatment paradigm in SLE over the next 3–5 years. I think the data are suitably strong to justify the approval of ...

pDCs are considered the primary source of IFN-α, which, as will be discussed below, makes them potentially very relevant to the immunopathology of SLE ... control B-cell proliferation ...